Key result
Stroke patients have significantly higher hs-CRP levels than non-stroke controls.
Why the study?
Inflammation plays a pivotal role in stroke progression, and high-sensitivity C-reactive protein (hs-CRP) shows promise as a biomarker requiring evaluation for its capacity to predict stroke and other cardiovascular events.
Does high-sensitivity C-reactive protein (hs-CRP) level predict stroke and other cardiovascular events compared with healthy controls?
Meta-Analysis (n=1,486)
Does high-sensitivity C-reactive protein (hs-CRP) level predict stroke and other cardiovascular events compared with healthy controls?
Elevated hs-CRP levels are significantly associated with both stroke and other cardiovascular events compared to healthy controls, supporting its role as a biomarker in cardiovascular and stroke risk prediction models.
Answers are grounded in this paper and cite their sources.
Elevated hs-CRP is associated with stroke; supports biomarker evaluation but leaves open incremental predictive value in models.
Background: Stroke stands as a prominent cause of morbidity and mortality on a global scale. Inflammation assumes a pivotal role in the advancement of stroke, with high-sensitivity C-reactive protein (hs-CRP) showing promise as a potential biomarker for assessing the risk of stroke. Aim: This meta-analysis seeks to evaluate the predictive capacity of hs-CRP in relation to stroke by comparing hs-CRP levels in stroke patients with those in non-stroke subjects (apparently healthy individuals) and patients with other cardiovascular events versus controls. Method: A comprehensive search across PubMed, Web of Science, EMBASE, and the Cochrane Library identified studies published from January 2010 to June 2024. Inclusion criteria focused on casecontrol or cohort studies reporting quantitative hs-CRP levels in stroke and cardiovascular events alongside control groups. Studies were rigorously screened and selected based on predefined criteria (randomised control trials). Data from 13 selected studies were extracted and analysed using RevMan 5.4.1 review manager. Findings: The meta-analysis included data from 13 studies with a total sample size of 1,486 subjects. The primary comparator analysis showed significantly higher hs-CRP levels in stroke patients than in non-stroke controls (Standardised Mean difference: 0.85 mg/L, 95% CI: 0.4,1.29; p= 0.0002). The secondary comparator analysis demonstrated elevated hs-CRP levels in patients who experienced other cardiovascular events compared to the control group (Standardised Mean Difference: 2.20 mg/L; 96% CI: 1.22, 3.18; p < 0.00001). These findings indicate that increased hs-CRP levels are associated with a heightened risk of stroke and other cardiovascular events. This underscores the potential of hs-CRP as a valuable biomarker in stroke and cardiovascular disease risk assessment. Conclusion: hs-CRP measurement can enhance stroke prediction models, facilitating early intervention and improving outcomes. Further research should focus on standardising hs-CRP measurement protocols and exploring their integration into clinical practice.
No takes yet. Share an insight, caveat, or question.
Abigail Biya (2026) conducted a meta-analysis in Stroke and other cardiovascular events (n=1,486). High-sensitivity C-reactive protein (hs-CRP) level vs. Non-stroke subjects (apparently healthy individuals) and controls was evaluated on Difference in hs-CRP levels between stroke patients and non-stroke controls (SMD 0.85 mg/L, 95% CI 0.4-1.29, p=0.0002). High-sensitivity C-reactive protein (hs-CRP) levels were higher in stroke patients than in non-stroke controls.
Synapse has enriched 10 related papers. Consider them for comparative context: